Provided by Tiger Trade Technology Pte. Ltd.

Xencor

24.41
+0.15000.62%
Post-market: 24.780.3700+1.52%19:30 EDT
Volume:905.27K
Turnover:22.06M
Market Cap:1.81B
PE:-11.21
High:24.84
Open:24.72
Low:23.96
Close:24.26
52wk High:30.61
52wk Low:8.26
Shares:74.13M
Float Shares:54.25M
Volume Ratio:0.75
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1768
EPS(LYR):-1.2400
ROE:-29.07%
ROA:-16.83%
PB:3.60
PE(LYR):-19.69

Loading ...

Bank of America Securities Reaffirms Their Hold Rating on Xencor (XNCR)

TIPRANKS
·
May 07

Xencor reports Q1 EPS ($1.71), consensus (75c)

TIPRANKS
·
May 07

Xencor Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Xencor Q1 EPS $(1.71) Misses $(0.75) Estimate, Sales $4.516M Miss $27.760M Estimate

Benzinga Earnings
·
May 07

Xencor Q1 net loss widens to $128.9 million; revenue drops to $4.5 million

Reuters
·
May 07

BRIEF-Xencor Q1 EPS USD -1.71

Reuters
·
May 07

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), DENTSPLY SIRONA (XRAY) and Neurocrine (NBIX)

TIPRANKS
·
May 06

Buy Rating on Xencor as TL1A Franchise Data and Upcoming Phase IIb Catalyst Support Upside Potential

TIPRANKS
·
May 06

Xencor to host webcast to discuss XmAb942, XmAb412 data presentations

TIPRANKS
·
May 04

Xencor schedules Phase 2b XmAb942 ulcerative colitis trial 12-week results for 2027

Reuters
·
May 04

Xencor announces annual shareholder meeting

Reuters
·
Apr 28

Top Xencor Executive Quietly Cashes Out a Chunk of Company Stock

TIPRANKS
·
Apr 14

Xencor Shares Fall After JPMorgan Downgrade

MT Newswires Live
·
Mar 25

Xencor Cut to Neutral From Overweight by JP Morgan

Dow Jones
·
Mar 24

JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18

MT Newswires Live
·
Mar 24

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR)

TIPRANKS
·
Mar 24

Xencor downgraded to Neutral from Overweight at JPMorgan

TIPRANKS
·
Mar 24

Xencor Inc : JP Morgan Cuts to Neutral From Overweight; Cuts Target Price to $13 From $18

THOMSON REUTERS
·
Mar 24

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Reuters
·
Mar 24